



YOUR CONSULTANT GUIDE

# GLP-1 support for our mutual clients



# Evernorth's suite of GLP-1 management options provide modularity in sustaining GLP-1 coverage—**combining financial sustainability and clinical efficacy**

The high prices, clinical complexity and unprecedented demand for GLP-1s has created unsustainable economic challenges. Evernorth has more cardiometabolic client offerings than the rest of the market—driving unit cost improvements while remaining co-preferred. All clients have a different approach when thinking through their GLP-1 for weight loss benefit strategy.

Whether clients prioritize trend management or accessing GLP-1s at direct-to-consumer-like price points, we offer optionality so clients can cover these life-changing medications in a way that meets their needs and budgets.

## WEIGHT LOSS

← BROADEST ACCESS		INCREASED CONTROL →		
Program	EncircleRx <sup>SM</sup> : Cardiodiabesity <sup>1</sup>	Advanced Utilization Management	Vendor+	EncircleRx: Cardiodiabesity
<b>Option type</b>	<b>Weight Loss: Highly Automated PA</b>	<b>PA to label Standard</b>	<b>No PA</b>	<b>Weight Loss: Trend Management</b> BMI only    BMI and Vendor
<b>Description</b>	Weight-loss GLP-1 coverage focused on the lowest available per-unit cost, including the option to increase member cost share up to \$200/30-day Rx.	Contains thousands of real-time safety edits to ensure patient safety and validates the appropriateness of medication.	Clients can leverage an existing weight loss vendor relationship to enable a narrow network of obesity care specialists who prescribe weight loss GLP-1s to clinically appropriate patients.	Elevates utilization management requirements and connects patient healthy habits to GLP-1 access.
<b>Net cost per Rx</b>	Low	Moderate	High	High
<b>Utilization</b>	High	Moderate	Low	Low
<b>Patient impact</b>	New to GLP-1 Titrating and maintenance	New to GLP-1	New to GLP-1 Maintenance-tailored ongoing support	New to GLP-1 Titrating and maintenance Discontinuation or renewal

# Managing spend while providing access with unprecedented demand for GLP-1s

## Changing the status quo. Together.

Driving optimal patient outcomes and client value by addressing GLP-1 challenges in a holistic way:



Ensuring consistent and predictable access to extended-day fills



Delivering value with improved outcomes



Removing waste and inappropriate use from the system




Providing patient-centric specialized clinical care

	CLINICAL PROGRAMS		A REIMAGINED CLINICAL STRUCTURE	
	All clinical programs outlined below can be enrolled in to provide the most robust set of GLP-1 management tools available.		Better addressing the complexities of medications like GLP-1s by bringing them to the market while also reimagining a reimbursement structure that allows pharmacies to dispense these medications to patients in a way that makes sense for their business.	
<b>Program</b>	<b>SafeGuardRx®</b>	<b>Patient Assurance Program®</b>	<b>Evernorth EnReachRx<sup>SM</sup></b>	<b>Evernorth EnGuide<sup>SM</sup> Pharmacy</b>
<b>GLP-1 focus</b>	Provides optional clinical support for patients and direct reimbursement to clients for any patient that discontinues these medications early.	Reducing out-of-pocket costs for participating weight loss products by up to 66% or more for many members.	Provides a high-touch patient support model around GLP-1 dispensing. Introduces new edits to target and eliminate waste while improving the patient experience.	A brand-new home delivery pharmacy dedicated to injectable GLP-1 medications.
<b>Category</b>	Clinical and financial value	Cost containment	Network	Pharmacy
<b>Patient impact</b>	Titrating and maintenance Discontinuation or renewal	Titrating and maintenance	New to GLP-1 Titrating and maintenance Discontinuation or renewal	

# Each program attacks problematic fraud, waste and abuse from a different angle, to triangulate the problem for the **broadest impact.**

FRAUD, WASTE AND ABUSE (FWA) COMPARISON<sup>2</sup>

	<b>Express Scripts® Pharmacy Benefit Services Enhanced FWA</b>	<b>EncircleRx FWA</b>	<b>EnGuide Enhanced Review</b>
<b>Data analytics</b>	Proactive data modeling to identify outlier members and prescribers across all drug types, which may indicate abuse or fraudulent use of the prescription drug benefit.	Proactive data modeling specifically targeting GLP-1s. Adds a 10-year lookback to analyze likelihood of a type 2 diabetes diagnosis, also reviews for known patterns of misuse.	Targeted analytics that trigger a unique alert at Evernorth EnGuide Pharmacy when provider NPI taxonomy and NDC match is outside norms.
<b>Investigation</b>	Thorough best-in-class investigations for suspected fraud, waste or abuse concerns. Examples include analysis of prescription claims, outreach to prescriber(s) and member(s), documentation from pharmacies, medical claim review, prior authorization review and internet research.	Detailed written investigation referral report to clients and law enforcement/medical boards (prescriber case only), as appropriate, if concerns of FWA are identified and substantiated.	Profile review of alerted scripts by pharmacists to evaluate for appropriate patient and prescriber relationship and appropriate use.
<b>Targeted education</b>	N/A	Written prescriber education specifically targeting GLP-1s. Sent to prescribers identified to be “high risk” of inappropriately prescribing or submitting falsified documentation for payment.	Telephonic prescriber outreach, if necessary, based on pharmacist review of specific alerted prescription. Focused on appropriate use and prescribing, also bringing prescriber awareness to patient’s fill patterns where applicable.
<b>Prescriber blocks</b>	Client-directed	Client-directed and automatic based on full FWA investigation	N/A



# Maximum optionality because all of our mutual clients are different

Our GLP-1 solutions are built to close gaps in care, manage costs, and improve health outcomes—while delivering unmatched flexibility to meet the diverse needs of our mutual clients and their members.



**11M+**  
people enrolled<sup>3</sup>

**2M+**  
pounds lost<sup>3</sup>

**7.7%**  
average BMI decrease<sup>3</sup>

**\$400M+**  
in client savings<sup>3</sup>

From open or closed networks to BMI criteria and a wide range of vendor partnerships, we offer customizable options tailored to unique populations.

With support for all branded GLP-1 therapies, providers and patients have the freedom to choose the treatment that best aligns with clinical goals and personal preferences.

**Up to 40% reduction** in client trend<sup>3</sup>

**80% of members** exceeded engagement benchmarks<sup>3</sup>

Partnered with **250+ providers** to raise awareness and improve prescribing practices<sup>3</sup>

**25% reduction** in high-risk prescribing in year one<sup>3</sup>



Work with your consultant relations director to talk through the best GLP-1 for weight loss benefit option for our mutual clients and patients.

\* Formerly referred to as the Cost Share option

1. EnReachRx enrollment required 2. Key features only, not a comprehensive review  
3. Evernorth Commercial Book of Business data, 2025

**EVERNORTH**  
HEALTH SERVICES